{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "52026579",
    "licUnit": "1",
    "validDate": "2025-12-11 00:00:00.000",
    "issueDate": "2015-12-11 00:00:00.000",
    "oriIssueDate": "2015-12-11",
    "licKind": "02",
    "oldLicid": null,
    "certNo": "DHA05202657909",
    "prodNameC": "泰伏樂膠囊75毫克",
    "prodNameE": "Tafinlar Capsules 75mg",
    "indicationsName": [
        "1. 黑色素瘤: Dabrafenib 單一療法或與trametinib 併用，可用於治療BRAF V600 突變陽性且無法以手術切除或轉移性的成人黑色素瘤 ( 請參閱第5.1 節)。\r\n2. 黑色素瘤的輔助治療: Dabrafenib 與trametinib 併用，可用於治療BRAF V600 突變且完全切除後之第III 期黑色素瘤病人的術後輔助治療。\r\n3. 非小細胞肺癌: Dabrafenib 與trametinib 併用，可用於治療BRAF V600 突變之晚期非小細胞肺癌成人病人。\r\n4.BRAF V600E突變陽性且無法切除或轉移性實體腫瘤：Dabrafenib與trametinib併用，可用於治療BRAF V600E突變之無法切除或轉移性實體腫瘤的6歲以上兒童及成人病人，前述病人於先前治療後出現惡化現象且無任何其他適當替代治療選擇。\r\n使用限制：Dabrafenib不可用於治療結腸直腸癌病人，因為這類病人已知對BRAF抑制作用具先天抗藥性。"
    ],
    "does": "1130",
    "packageUnit": [
        {
            "packageSpec": "8-1000粒",
            "packageUnit": "A3"
        }
    ],
    "medMCode": "06",
    "maMedCode": "",
    "medDCode": null,
    "mainCategory": null,
    "drBaseId": "52077D91-E64C-4B98-9317-CC5873F7D5CF",
    "subCategory": [],
    "ingredientsDesc": [
        "Dabrafenib Mesylate (Micronized)"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "07 新藥監視",
        "5F 免除銜接性試驗",
        "67 成品已完成元素不純物評估(Option 1、2a、2b)"
    ],
    "applicantName": "台灣諾華股份有限公司",
    "applicantAddr": "臺北市中山區民生東路3段2號8樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": null,
    "mdKind": [],
    "monitorDate": "2020-12-11",
    "licidNew": null,
    "licidOld": null,
    "manuImportDesc": "廠商未登錄資料",
    "licManuImport": "2",
    "factoryDtoList": [
        {
            "id": "A9C8987D-D6D5-4929-9F93-A88FC32D8ADE",
            "factoryCode": "1",
            "factoryName": "Novartis Pharmaceutical Manufacturing LLC",
            "factoryAddr": "Verovskova ulica 57 1000 Ljubljana Slovenia",
            "factoryCompanyAddr": null,
            "countryCode": "SI",
            "processCode": [
                {
                    "value": "2P",
                    "name": "成品製造、一級包裝、二級包裝"
                }
            ],
            "processCodeStr": "2P;成品製造、一級包裝、二級包裝",
            "factoryKind": "M",
            "factoryNo": "FSI0008000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "53BA4036-A717-41D4-ACC1-F4D6FED7E327",
            "factoryCode": "2",
            "factoryName": "裕利股份有限公司",
            "factoryAddr": "桃園市大園區和平里1鄰開和路91號",
            "factoryCompanyAddr": null,
            "countryCode": "TW",
            "processCode": [
                {
                    "value": "3P",
                    "name": "二級包裝廠(委託貼標及置入仿單)"
                }
            ],
            "processCodeStr": "3P;二級包裝廠(委託貼標及置入仿單)",
            "factoryKind": "M",
            "factoryNo": "6132061151",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013005310",
            "ingredientsName": "Dabrafenib Mesylate (Micronized)",
            "ingredientsDesc": "Dabrafenib Mesylate (Micronized)",
            "concentDesc": "(eq. to Dabrafenib..….75 MG)",
            "concent": "88.880000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01EC02"
        }
    ],
    "licBaseId": "4FCB50B1-1A94-4EC9-B45C-CBDAEE014196"
}